Dermatology Update 2017 Fall
SESSIONS & ABSTRACTS
VANCOUVER, FAIRMONT WATERFRONT HOTEL - OCTOBER 26-29, 2017
EXPOSED: Uncovering the Facts about Psoriasis Management with IL-17 Inhibitors
The overarching goal of this session is to highlight the importance of treatment optimization, to increase awareness of emerging therapies and to improve the care of patients with moderate to severe psoriasis.
The session will serve as a vehicle to reinforce awareness and understanding of the mode of action of IL-17 inhibitors, their efficacy, key benefits, and safety considerations. The program will be highly interactive to promote in-depth discussion on the subject matter and designed to test current knowledge and promote reflection. The session will incorporate short data presentations, panel discussions and participant polling questions.
Upon completion of this activity, participants will be able to:
- Discuss the role for IL-17 inhibitors, including treatment optimization.
- Evaluate and assess new clinical trial data regarding the efficacy and safety profiles of biologics targeting the IL-17 pathway.
- Apply practical approaches to using IL-17 inhibitors in daily practice.
|11:00-11:10||Introduction||Dr. Marc Bourcier|
|11:10-11:25||Treatment gaps and unmet needs||Dr. Chih-ho Hong|
|11:25-11:30||Panel discussion||Led by Dr. Marc Bourcier|
|11:30-11:45||IL-17 efficacy, new data||Dr. Melinda Gooderham|
|11:45-11:50||Panel discussion||Led by Dr. Marc Bourcier|
|11:50-12:05||IL-17 safety and practical considerations||Dr. Marni Wiseman|
|12:05-12:10||Panel discussion||Led by Dr. Marc Bourcier|
|12:10-12:15||Closing remarks||Dr. Marc Bourcier|
Dermatologist, Moncton, New Brunswick
Dermatologist, Surrey, British Columbia
Dermatologist, Peterborough, Ontario